KRT18 and metabolic dysfunction-associated steatohepatitis: A randomized trial of patients with T2DM who received tirzepatide revealed significant decreases in biomarkers related to NASH such as AST/ALT, procollagen III, keratin 18, and an increase in adiponectin levels, which is believed to activate antifibrotic and antisteatogenic effects in the liver [106].